Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Depreciation & Amortization (CF) (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed Depreciation & Amortization (CF) for 11 consecutive years, with $954000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 12.07% to $954000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.1 million through Dec 2025, down 24.41% year-over-year, with the annual reading at $4.1 million for FY2025, 24.41% down from the prior year.
  • Depreciation & Amortization (CF) hit $954000.0 in Q4 2025 for Seres Therapeutics, down from $1.0 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.7 million in Q3 2022 to a low of $954000.0 in Q4 2025.
  • Historically, Depreciation & Amortization (CF) has averaged $1.4 million across 5 years, with a median of $1.5 million in 2021.
  • Biggest five-year swings in Depreciation & Amortization (CF): increased 18.16% in 2022 and later crashed 33.52% in 2024.
  • Year by year, Depreciation & Amortization (CF) stood at $1.6 million in 2021, then grew by 4.83% to $1.6 million in 2022, then grew by 0.31% to $1.6 million in 2023, then crashed by 33.52% to $1.1 million in 2024, then dropped by 12.07% to $954000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for MCRB at $954000.0 in Q4 2025, $1.0 million in Q3 2025, and $1.1 million in Q2 2025.